WeVote
Log In

Bill

Bill

HB 1684

Creates provisions relating to over-the-counter purchase of ivermectin

2026 Regular Session Introduced by Burt Whaley

Ivermectin tablets would be available OTC in Missouri without a prescription or pharmacist consultation.

Referred: Emerging Issues(H)
#drugsandcontrolledsubstances #healthcare #health #public
0
WeVote Research Nonpartisan
Bill Summary · HB 1684

Summary — HB 1684 (Missouri version): Over‑the‑counter purchase of ivermectin tablets

Note: Multiple bills numbered HB 1684 appear in the provided materials from different states (Arkansas, Indiana, Illinois). This summary focuses on the Missouri HB 1684 text included in the documents, which would add section 195.1000 to Chapter 195, RSMo — a provision concerning over‑the‑counter access to ivermectin tablets.

Main purpose

To require that ivermectin tablets be made available to the public for purchase over the counter (OTC) in Missouri without a prescription or any consultation with a pharmacist or other health care professional.

Key statutory change

  • Adds a new section, RSMo 195.1000, with the sole operative sentence:
    • “Notwithstanding any other provision of law, ivermectin tablets shall be available to the public through over‑the‑counter purchase in this state without a prescription or consultation with a pharmacist or other health care professional.”
  • The “notwithstanding” clause indicates this provision would supersede conflicting state laws on prescription/dispensing requirements for ivermectin tablets.

Who would be affected

  • Consumers/public: would be able to purchase ivermectin tablets without a prescription or professional consultation.
  • Pharmacies, retailers, and distributors: would be able to sell ivermectin tablets OTC; may need to change purchasing, stocking, and point‑of‑sale procedures.
  • Prescribers and pharmacists: statutory limitation on requiring a prescription or consultation for ivermectin tablets.
  • Regulators and insurers: potential implications for drug classification, coverage, and labeling/packaging oversight.
  • Public health entities: potential effects on medication misuse, off‑label use, and safety monitoring.

Notable omissions and practical implications

  • The text does not specify: age limits, quantity limits, labeling/warning requirements, packaging (human vs. veterinary formulations), dosage guidance, or restrictions on sale locations.
  • Because it bars required consultation, it also bars pharmacist discretion requiring counseling before sale.
  • The bill may create conflicts with existing state regulatory rules or professional practice standards due to the “notwithstanding” language.
  • Safety, misuse, and public‑health monitoring concerns could arise given ivermectin’s approved uses and existing FDA guidance.

Legislative status and timeline (per provided actions)

  • House actions: read/considered and (per the record) passed by the House and transmitted to the Senate (House passage noted 2025‑03‑20).
  • Senate actions: referred to committee; the bill ultimately “Died in Senate Committee at Sine Die adjournment” (listed 2025‑05‑05).
  • Sponsor listed in the Missouri text: Representative Whaley.

If you want, I can:
- Draft a side‑by‑side comparison of this bill’s language with current Missouri pharmacy/prescription statutes;
- List likely regulatory or legal questions the Missouri Board of Pharmacy or Attorney General would face if enacted;
- Summarize public‑health and clinical guidance about ivermectin to illustrate safety considerations.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.